ALK and lung adenocarcinoma: Using targeted next-generation sequencing (NGS) of 1021 cancer-related genes, we found the emergence of a BRAF V600E mutation in the peripheral blood of a patient with ALK-rearranged lung adenocarcinoma after treatment progression on ALK-TKIs, which may explain the resistance.